Condition
Resectable Non-Small-Cell Lung Cancer
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04198766Phase 1Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT05633667Phase 2Active Not Recruiting
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT06607926Not ApplicableNot Yet RecruitingPrimary
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Showing all 3 trials